Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERACLES-RESCUE
2015-003275-30Phase 2Completed
- Sponsor
- Fondazione del Piemonte per l'Oncologia
- Start
- Jan 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC), colon adenocarcinoma and 1 more, sponsored by Fondazione del Piemonte per l'Oncologia. Primary endpoint: Objective response rate. Started Jan 2021; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2015-003275-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003275-30.